Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Cost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsReceivables - NetReceivables - OtherShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Caris Life Sciences (CAI) Cost of Revenue (2024 - 2025)

Caris Life Sciences has reported Cost of Revenue over the past 2 years, most recently at $44.2 million for Q4 2025.

  • Quarterly results put Cost of Revenue at $44.2 million for Q4 2025, up 17.66% from a year ago — trailing twelve months through Dec 2025 was $165.2 million (changed N/A YoY), and the annual figure for FY2025 was $167.5 million, up 9.77%.
  • Cost of Revenue for Q4 2025 was $44.2 million at Caris Life Sciences, up from $41.3 million in the prior quarter.
  • Over the last five years, Cost of Revenue for CAI hit a ceiling of $44.2 million in Q4 2025 and a floor of $36.8 million in Q3 2024.